PMID- 33995848
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210518
IS  - 1948-9358 (Print)
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 12
IP  - 5
DP  - 2021 May 15
TI  - Current advances in using tolerogenic dendritic cells as a therapeutic 
      alternative in the treatment of type 1 diabetes.
PG  - 603-615
LID - 10.4239/wjd.v12.i5.603 [doi]
AB  - Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction 
      of insulin-producing beta-cells of the pancreatic islets by autoreactive T cells, 
      leading to high blood glucose levels and severe long-term complications. The 
      typical treatment indicated in T1D is exogenous insulin administration, which 
      controls glucose levels; however, it does not stop the autoimmune process. 
      Various strategies have been implemented aimed at stopping beta-cell destruction, 
      such as cellular therapy. Dendritic cells (DCs) as an alternative in cellular 
      therapy have gained great interest for autoimmune disease therapy due to their 
      plasticity to acquire immunoregulatory properties both in vivo and in vitro, 
      performing functions such as anti-inflammatory cytokine secretion and suppression 
      of autoreactive lymphocytes, which are dependent of their tolerogenic phenotype, 
      displayed by features such as semimature phenotype, low surface expression of 
      stimulatory molecules to prime T cells, as well as the elevated expression of 
      inhibitory markers. DCs may be obtained and propagated easily in optimal amounts 
      from peripheral blood or bone marrow precursors, such as monocytes or 
      hematopoietic stem cells, respectively; therefore, various protocols have been 
      established for tolerogenic (tol)DCs manufacturing for therapeutic research in 
      the treatment of T1D. In this review, we address the current advances in the use 
      of tolDCs for T1D therapy, encompassing protocols for their manufacturing, the 
      data obtained from preclinical studies carried out, and the status of clinical 
      research evaluating the safety, feasibility, and effectiveness of tolDCs.
CI  - (c)The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Rios-Rios, William de Jesus
AU  - Rios-Rios WJ
AD  - Department of Biochemical Sciences Faculty, Universidad Autonoma "Benito Juarez" 
      de Oaxaca, Oaxaca 68120, Mexico.
FAU - Sosa-Luis, Sorely Adelina
AU  - Sosa-Luis SA
AD  - Department of Molecular Biomedicine, Centro de Investigacion y de Estudios 
      Avanzados del Instituto Politecnico Nacional, Mexico City 07360, Mexico.
FAU - Torres-Aguilar, Honorio
AU  - Torres-Aguilar H
AD  - Department of Biochemical Sciences Faculty, Universidad Autonoma "Benito Juarez" 
      de Oaxaca, Oaxaca 68120, Mexico. qbhonorio@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC8107985
OTO - NOTNLM
OT  - Autoimmunity
OT  - Cell therapy
OT  - Dendritic cells
OT  - Immune tolerance
OT  - Immunotherapy.
OT  - Type 1 diabetes
COIS- Conflict-of-interest statement: The authors have declared having no conflicts of 
      interest.
EDAT- 2021/05/18 06:00
MHDA- 2021/05/18 06:01
PMCR- 2021/05/15
CRDT- 2021/05/17 06:08
PHST- 2021/01/21 00:00 [received]
PHST- 2021/02/26 00:00 [revised]
PHST- 2021/04/20 00:00 [accepted]
PHST- 2021/05/17 06:08 [entrez]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/05/18 06:01 [medline]
PHST- 2021/05/15 00:00 [pmc-release]
AID - 10.4239/wjd.v12.i5.603 [doi]
PST - ppublish
SO  - World J Diabetes. 2021 May 15;12(5):603-615. doi: 10.4239/wjd.v12.i5.603.